Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240187 | 0.93 | DNM1 (0.44) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL7920911 | 0.91 | DNM1 (0.48) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL1241227 | 0.91 | DNM1 (0.42) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL9161823 | 0.91 | DNM1 (0.48) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL18941461 | 0.91 | DNM1 (0.48) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL1403907 | 0.91 | DNM1 (0.48) | DNM1CA12CA1CA9CA2 | |
| Hydrochloric Acid SCHEMBL28919675 | 0.89 | DNM1 (0.50) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL16105752 | 0.85 | DNM1 (0.35) | DNM1CA12CA1CA9ALDH1A1 | |
| SCHEMBL17622993 | 0.84 | — | — | |
| SCHEMBL7528493 | 0.84 | TSHR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2784059-B1 | Method for isolating tertiary amino alcohol | TOSHIBA KK (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9181174-B2 | Method for isolating tertiary amino alcohol | KABUSHIKI KAISHA TOSHIBA (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20140296576-A1 | METHOD FOR ISOLATING TERTIARY AMINO ALCOHOL | KABUSHIKI KAISHA TOSHIBA (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2784059-A1 | Method for isolating tertiary amino alcohol | Kabushiki Kaisha Toshiba (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
| EP-0668271-B1 | Process for the preparation of isocyanurate-group containing polyisocyanates | BASF AG (DE) | 2002-01-16 | — | — | EP | disclosed |
| US-5489663-A | TRIMERIZING ALIPHATIC AND/OR CYCLOALIPHATIC DIISOCYANATES USING TETRAALKYLAMMONIUM ALKYL CARBONATE OR MIXTURES WITH QUATERNARY AMMONIOALKYL CARBONATE CATALYSTS, DEACTIVATING CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-06 | — | — | US | disclosed |
| EP-0400435-B1 | Carbonic half-ester of betaine structure | BASF AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0400435-A2 | Carbonic half-ester of betaine structure | BASF Aktiengesellschaft (DE) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296576-A1 | METHOD FOR ISOLATING TERTIARY AMINO ALCOHOL | ADH1C, AADAT, ADH1A | DNM1 1211/4885CA12 3128/4885CA1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.